Lineage Cell (NYSE: LCTX) signs WDI pact for ReSonance ANPI

Rhea-AI Filing Summary

Lineage Cell Therapeutics disclosed a new multi-year research collaboration with William Demant Invest 2 Aps (WDI) to advance its auditory neuronal cell transplant program, ReSonance (ANPI), aimed at treating hearing loss. WDI has agreed to fund up to $12 million in research collaboration costs over an approximate three-year term.

The collaboration focuses on completing preclinical work so the program may be ready to progress to human clinical trials under future clinical agreements to be negotiated in good faith. Each party keeps ownership of its existing intellectual property, while Project Results will generally be jointly owned, with specific provisions allowing one party to buy out the other’s interest if it decides not to continue into clinical development.

Insights

Biotech partnerships and IP strategy analyst

Lineage secures up to $12M external funding for preclinical hearing-loss program.

Lineage Cell Therapeutics has entered a research collaboration with WDI to fund and advance its ReSonance (ANPI) auditory neuronal cell transplant program for hearing loss. WDI will fund up to $12 million of research costs over an approximately three-year term, which helps support preclinical development without drawing solely on Lineage’s own capital.

The stated objective is to complete a preclinical phase positioned for potential human clinical trials, subject to negotiating one or more separate clinical agreements before the collaboration expires. This structure ties longer-term progress to future negotiations, so outcomes will depend on the parties reaching agreement on clinical terms.

Intellectual property is handled with each side retaining prior assets, while most Project Results are jointly owned. A mechanism allows a continuing party to purchase the other’s Project IP interest and obtain a license to its background IP for hearing-loss use if one side opts not to move forward clinically, which could help avoid deadlock around future development paths.

0000876343false00008763432025-08-262025-08-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 26, 2025

Lineage Cell Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

California			001-12830	94-3127919
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
2173 Salk Avenue, Suite 200
Carlsbad, California				92008
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (442) 287-8990

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares		LCTX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 26, 2025, Lineage Cell Therapeutics, Inc. (“we,” “us,” “our,” the “Company,” or “Lineage”) issued a press release announcing that it entered into a multi-year research collaboration agreement with William Demant Invest 2 Aps (“WDI”) to advance the preclinical development of Lineage’s auditory neuronal cell transplant program, ReSonanceTM (ANPI), for the treatment of hearing loss. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and in Exhibit 99.1 to this report is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On August 22, 2025, Lineage and WDI entered into a research collaboration agreement (the “RCA”) to advance the preclinical development of Lineage’s auditory neuronal cell transplant program, ReSonance (ANPI), for the treatment of hearing loss (the “Project”). WDI will fund up to $12 million in research collaboration costs over the approximate three-year term of the RCA. The main objective of the RCA is for the parties to complete a preclinical phase achieving readiness to potentially progress to human clinical trials under one or more separate clinical agreements, the terms of which would be negotiated in good faith before the expiration of the RCA.

All intellectual property owned by a party prior to the date of the RCA will remain their sole and exclusive property. The parties will jointly own all results, data, reports, know-how and patent(s) conceived or otherwise generated in the course of and resulting from the Project (the “Project Results”), other than discoveries or developments relating to Lineage's prioprietary platform technology.

If a party (the “abandoning party”) informs the other party (the “continuing party”) that it will not continue the research with the other party under a clinical agreement, the continuing party may purchase the abandoning party’s ownership interest in the intellectual property resulting from the Project for exploitation for the treatment of hearing loss and a license to the abandoning party’s background intellectual property to the extent necessary for such exploitation for an amount and on terms to be determined by the mutual agreement of the parties, and if such mutual agreement is not reached, by an independent third-party.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release issued on August 26, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Lineage Cell Therapeutics, Inc.
Date:	August 26, 2025	By:	/s/ George A. Samuel III
		Name: Title:	George A. Samuel III General Counsel and Corporate Secretary

FAQ

What did Lineage Cell Therapeutics (LCTX) announce in this 8-K?

Lineage Cell Therapeutics announced a multi-year research collaboration agreement with William Demant Invest 2 Aps (WDI) to advance its ReSonance (ANPI) auditory neuronal cell transplant program for the treatment of hearing loss.

How much funding will WDI provide to Lineage Cell Therapeutics under the collaboration?

Under the research collaboration agreement, WDI will fund up to $12 million in research collaboration costs over an approximate three-year term.

What is the main goal of the Lineage and WDI research collaboration?

The main goal is to complete a preclinical phase of the ReSonance (ANPI) program so it is ready to potentially progress to human clinical trials, which would be governed by future clinical agreements negotiated in good faith.

How is intellectual property handled in the Lineage–WDI collaboration?

Each party keeps sole ownership of its pre-existing intellectual property. Project Results, such as data and patents generated from the collaboration, will generally be jointly owned, except for discoveries related to Lineage’s proprietary platform technology.

What happens if one party does not want to continue into clinical development?

If one party chooses not to continue research under a clinical agreement, the other party may purchase that party’s ownership interest in the Project intellectual property for hearing-loss uses and obtain a related background IP license, with terms set by mutual agreement or an independent third party.

What stage of development is the ReSonance (ANPI) program targeting under this agreement?

The company included Exhibit 99.1, which is the press release issued on August 26, 2025 discussing the research collaboration with WDI.